Source-grounded facts extracted from Vicarious Surgical Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dr. Barry Greene was terminated as Chief Medical Officer at Vicarious Surgical Inc..
“the Company terminated the employment of each of Stephen From, the Company’s Chief Executive Officer, Adam Sachs, the Company’s President, Sammy Khalifa, the Company’s Chief Technology Officer, and Dr. Barry Greene, the Company’s Chief Medical Officer, effective as of the close of business on July 21, 2026.”
Sammy Khalifa was terminated as Chief Technology Officer at Vicarious Surgical Inc..
“the Company terminated the employment of each of Stephen From, the Company’s Chief Executive Officer, Adam Sachs, the Company’s President, Sammy Khalifa, the Company’s Chief Technology Officer, and Dr. Barry Greene, the Company’s Chief Medical Officer, effective as of the close of business on July 21, 2026.”
Adam Sachs was terminated as President at Vicarious Surgical Inc..
“the Company terminated the employment of each of Stephen From, the Company’s Chief Executive Officer, Adam Sachs, the Company’s President, Sammy Khalifa, the Company’s Chief Technology Officer, and Dr. Barry Greene, the Company’s Chief Medical Officer, effective as of the close of business on July 21, 2026.”
Stephen From was terminated as Chief Executive Officer at Vicarious Surgical Inc..
“the Company terminated the employment of each of Stephen From, the Company’s Chief Executive Officer, Adam Sachs, the Company’s President, Sammy Khalifa, the Company’s Chief Technology Officer, and Dr. Barry Greene, the Company’s Chief Medical Officer, effective as of the close of business on July 21, 2026.”
Fuad Ahmad resigned as Director at Vicarious Surgical Inc..
“each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).”
Victoria Carr-Brendel resigned as Director at Vicarious Surgical Inc..
“each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).”
David Ho resigned as Director at Vicarious Surgical Inc..
“each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).”
Sammy Khalifa resigned as Director at Vicarious Surgical Inc..
“each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).”
Adam Sachs resigned as Director at Vicarious Surgical Inc..
“each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).”
Stephen From resigned as Director at Vicarious Surgical Inc..
“each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).”
Joseph Doherty resigned as Director at Vicarious Surgical Inc..
“each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).”
Sarah Romano resigned as Chief Financial Officer at Vicarious Surgical Inc..
“On June 24, 2026, Sarah Romano notified the Board of Directors of her resignation as Chief Financial Officer of the Company, effective July 22, 2026, or such later date as may be mutually agreed upon by the Company and Ms. Romano.”
Vicarious Surgical Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income GAAP net loss in the fourth quarter of 2025 was $10.5 million, EPS GAAP net loss per share of $1.57.
“On March 9, 2026, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the fiscal year and fourth fiscal quarter ended December 31, 2025.”
Vicarious Surgical Inc. received a nyse delisting notice notice regarding market value (rules 802.01B).
“March 3, 2026, the New York Stock Exchange (the “NYSE”) notified Vicarious Surgical Inc. (the “Company”) that the NYSE had determined to (A) immediately suspend trading in the Company’s common stock, par value $0.0001 per share (the “Common Stock”), due to a determination that the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Commo”
Vicarious Surgical Inc. entered into At the Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2025-12-12).
“On December 12, 2025, Vicarious Surgical Inc., a Delaware corporation (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”) providing for the sale by the Company of its shares of Class A common stock”
Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).
“YSE’s determination. Trading in the Company’s Common Stock will be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026, and continued compliance with the NYSE’s other continued listing requirements.”
Vicarious Surgical Inc. received a nyse delisting notice notice regarding other (rules 802.01D).
“December 15, 2025, the NYSE notified the Company that the NYSE has determined to (a) commence proceedings to delist the Company’s warrants, with thirty warrants exercisable for one share of Common Stock, at an exercise price of $345.00 per share, and listed to trade on the NYSE under the symbol “RBOT.WS” (the “Public Warrants”) and (b) immediately suspend trading in the Public Warrants due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Common Stock w”
Vicarious Surgical Inc. issued Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.
“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”
Vicarious Surgical Inc. issued Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.
“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”
Vicarious Surgical Inc. issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 561,700 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.
“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”
Vicarious Surgical Inc. issued 588,300 shares of common stock to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.
“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”
Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).
“April 10, 2025, Vicarious Surgical Inc. (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company was no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. In accordance with applicable NYSE p”
Vicarious Surgical Inc. engaged Cherry Bekaert LLP as its auditor.
“On July 7, 2025, in connection with the Company’s dismissal of Deloitte, the Audit Committee approved the engagement of Cherry Bekaert as its new independent registered public accounting firm”
Vicarious Surgical Inc. dismissed Deloitte & Touche LLP as its auditor.
“On July 7, 2025, the Company dismissed Deloitte & Touche LLP ("Deloitte") as the Company’s independent registered public accounting firm.”
Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).
“April 10, 2025, Vicarious Surgical, Inc. (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company is no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. As described in the Notice, as of Ap”
Randy Clark was appointed as Director at Vicarious Surgical Inc..
“the Company’s Board of Directors (the “Board”) has appointed Mr. Clark to the Board, effective as of April 25, 2025, pending customary conflict checks.”
Randy Clark resigned as President at Vicarious Surgical Inc..
“On March 18, 2025, Randy Clark resigned as President of Vicarious Surgical Inc. (the “Company”), effective as of April 25, 2025.”
Sarah Romano was appointed as Chief Financial Officer and Treasurer at Vicarious Surgical Inc..
“On March 13, 2025, Vicarious Surgical Inc. (the “Company”) announced that Sarah Romano was appointed by the Board of Directors of the Company (the “Board”) as Chief Financial Officer and Treasurer of the Company, effective April 1, 2025”
John Mazzola departed as Chief Operating Officer at Vicarious Surgical Inc..
“On February 12, 2025, John Mazzola notified the Company that he intends to retire from his position as Chief Operating Officer of Vicarious Surgical Inc. (the “Company”), effective April 1, 2025.”
William Kelly departed as Chief Financial Officer at Vicarious Surgical Inc..
“On January 17, 2025, Vicarious Surgical Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with William Kelly in connection with Mr. Kelly’s previously disclosed departure from his role as Chief Financial Officer of the Company.”
Vicarious Surgical Inc. reported the quarter ended March 31, 2024 results: net income GAAP net loss for the first quarter was $17.0 million, equating to a net loss per share of $0.10, EPS $0.10. Guidance reaffirmed.
“Vicarious Surgical Reports First Quarter 2024 Financial Results”
Vicarious Surgical Inc. reported fourth quarter and full year ended December 31, 2023 results: net income GAAP net loss for the fourth quarter was $13.1 million, equating to a net loss per share of $0.06, as compared to a GAAP, EPS GAAP net loss for the fourth quarter was $13.1 million, equating to a net loss per share of $0.06, as compared to a GAAP. Guidance reaffirmed.
“On March 4, 2024, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023 and providing a business update.”
David Styka resigned as Executive Chairman at Vicarious Surgical Inc..
“On February 27, 2024, David Styka notified the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”) of his intent to resign as executive chairman and member of the Board, effective February 29, 2024.”
Adam Sachs changed role as President at Vicarious Surgical Inc..
“In connection with the appointment of Mr. Clark, Adam Sachs stepped down from his role as President.”
Randy Clark was appointed as President at Vicarious Surgical Inc..
“On January 29, 2024, Vicarious Surgical Inc. (the “Company”) announced the appointment of Randy Clark as the President of the Company, effective as of the same day”
Vicarious Surgical Inc. reported the quarter ended September 30, 2023 results: net income GAAP net loss for the third quarter was $15.7 million, equating to a net loss per share of $0.10, EPS net loss per share of $0.10. Guidance reaffirmed.
“Vicarious Surgical Reports Third Quarter 2023 Financial Results”
Vicarious Surgical Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).
“September 20, 2023, Vicarious Surgical Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the average per share trading price of its Class A common stock (the “Class A common stock”) was below the NYSE’s continued listing standard rule relating to minimum average share price. Rule 802.01C of the NYSE’s Listed Company Manual requires that a company’s common stock trade at a minimum average closing price of $1.00 over a consecutive 30 trading-day period. Pursuant to Section 802.01C, the Company has a period of six months following the receipt o”
Vicarious Surgical Inc. reported second quarter ended June 30, 2023 results: net income $15.3 million, EPS $0.12.
“GAAP net loss for the second quarter was $15.3 million, equating to a net loss per share of $0.12, as compared to a GAAP net loss of $1.5 million, equating to a net loss per share of $0.01 for the same period of the prior year.”
Vicarious Surgical Inc.: Limited liability of officers as permitted by recent amendments to Delaware law (effective 2023-06-06).
“On June 6, 2023, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation with the Secretary of State of the State of Delaware to limit the liability of its officers as permitted by recent amendments to Delaware law (the “Charter Amendment”).”
John Mazzola was appointed as Chief Operating Officer at Vicarious Surgical Inc..
“On May 18, 2023, Vicarious Surgical Inc. (the “Company”) announced the appointment of John Mazzola as the Chief Operating Officer of the Company, effective as of the same day.”
Vicarious Surgical Inc. reported first quarter ended March 31, 2023 results: net income $26.9 million, EPS $0.21. Guidance reaffirmed.
“GAAP net loss for the first quarter was $26.9 million, equating to a net loss per share of $0.21, as compared to a GAAP net income of $42.5 million, equating to a basic and diluted net income per share of $0.35 and $0.33 respectively for the same period of the prior year.”
Vicarious Surgical Inc. reported the fourth quarter and year ended December 31, 2022 results: net income GAAP net loss for the fourth quarter was $11.2 million, equating to a net loss per share of $0.09, EPS a net loss per share of $0.09.
“GAAP net loss for the fourth quarter was $11.2 million, equating to a net loss per share of $0.09, as compared to a GAAP net income of $21.8 million or a net income per share of $0.18 for the same period of the prior year.”
Philip Liang resigned as Director at Vicarious Surgical Inc..
“Philip Liang, a member of the Board, notified the Company that he is resigning from the Board, effective as of January 23, 2023.”
Victoria Carr-Brendel was appointed as Director at Vicarious Surgical Inc..
“appointed Victoria Carr-Brendel, Ph.D. to the Board, effective as of January 23, 2023.”
Vicarious Surgical Inc. reported third quarter ended September 30, 2022 results: net income Net loss for the third quarter was $24.7 million, equating to a basic and diluted net loss per share of $0.20, EPS $0.20.
“On November 7, 2022, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the third quarter ended September 30, 2022 and providing a business update.”
Beverly A. Huss was appointed as Director at Vicarious Surgical Inc..
“On October 18, 2022, the Board appointed Beverly A. Huss to the Board, effective as of the same date, to fill one of the vacancies created by the departures of Mr. Kaul and Mr. Berman.”
Dror Berman resigned as Director at Vicarious Surgical Inc..
“Samir Kaul and Dror Berman, members of the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”), each notified the Company that he is resigning from the Board, effective October 18, 2022 .”
Samir Kaul resigned as Director at Vicarious Surgical Inc..
“Samir Kaul and Dror Berman, members of the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”), each notified the Company that he is resigning from the Board, effective October 18, 2022 .”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.